person · Reporting owner

Doyle Mittie

Disclosed activity across 3 companies

Tapewire entity: 17865
SEC CIK: 0001918845

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalo Therapeutics, Inc.AVTX · Entity 4936	Chief Medical Officer	August 28, 2026	September 01, 2026
Cullinan Therapeutics, Inc.CGEM · Entity 4766	Director	June 16, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalo Therapeutics, Inc.

Report date August 28, 2026 · Filed September 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	51,776	Ending reported balance After 2026-08-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-28 · Exercise / conversion · Acquired 679 · Balance 52,455 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. Row 2 · 2026-08-28 · Sale · Disposed 679 · Balance 51,776 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 · Expires 2035-01-28	Direct	113,734	Reported balance After 2026-08-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-28 · Exercise / conversion · Disposed 679 · Balance 113,734 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. F2: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F2: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Cullinan Therapeutics, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2026-06-16	Direct	21,781	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 21,781 · Balance 21,781 F1: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

DICE Therapeutics, Inc.

Report date August 09, 2023 · Filed August 09, 2023

Section 16 reporting ended · disclosed 2023-08-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2032-03-31	Direct	0	Reported balance After 2023-08-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-08-09 · Disposition to issuer · Disposed 42,500 · Balance 0 F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant.

Filing footnotes · ownership attribution and instrument terms

F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested.

F3: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant.

F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 16, 2026 Filed Mar 18, 2026 20:07 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	Exercise / conversionStock Option (Right to Buy) · Derivative	19,500	$0.00 Strike: $12.65	$0.00	Disclosure SEC source: 0001918845-26-000004 · form4-03182026_080310.xml · derivative · entry 4 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,500 Underlying: Common Stock · 19,500 shares Expires 2034-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:07 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	SaleCommon Stock	25,492	$16.15	$411,606.58	Disclosure SEC source: 0001918845-26-000004 · form4-03182026_080310.xml · nonDerivative · entry 3 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,622 F1 · price: The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:07 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	Exercise / conversionCommon Stock	5,992	$8.04	$48,175.68	Disclosure SEC source: 0001918845-26-000004 · form4-03182026_080310.xml · nonDerivative · entry 2 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2026 Filed Mar 18, 2026 20:07 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	Exercise / conversionCommon Stock	19,500	$12.65	$246,675.00	Disclosure SEC source: 0001918845-26-000004 · form4-03182026_080310.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 26, 2026 Filed Mar 2, 2026 21:23 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	GrantStock Option (Right to Buy) · Derivative	105,000	$0.00 Strike: $17.64	$0.00	Disclosure SEC source: 0001918845-26-000002 · form4-03022026_090303.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document
December 10, 2025 Filed Dec 12, 2025 21:18 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	Tax withholdingCommon Stock	1,013	$4.10	$4,153.30	Disclosure SEC source: 0001470831-25-000412 · form4.xml · nonDerivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,622 F1 · balance_after: Includes 3,622 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document
August 07, 2025 Filed Aug 8, 2025 21:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	GrantStock Option (Right to Buy) · Derivative	79,456	$0.00 Strike: $7.03	$0.00	Disclosure SEC source: 0000950170-25-106028 · ownership.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,456 Underlying: Common Stock · 79,456 shares Expires 2035-08-07 F1 · derivative.exercise_date: The option represents a right to purchase a total of 79,456 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date. Read SEC document
January 28, 2025 Filed Jan 30, 2025 22:20 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	GrantStock Option (Right to Buy) · Derivative	155,000	$0.00 Strike: $8.04	$0.00	Disclosure SEC source: 0001578563-25-000026 · primary_doc.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document
July 15, 2024 Filed Jul 16, 2024 20:23 UTC	Avalo Therapeutics, Inc. AVTX · Entity 4936	GrantStock Option (Right to Buy) · Derivative	234,000	$0.00 Strike: $12.65	$0.00	Disclosure SEC source: 0001578563-24-000331 · primary_doc.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,000 Underlying: Common Stock · 234,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Option Shares vest on July 15, 2025 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date. Read SEC document
August 09, 2023 Filed Aug 9, 2023 16:21 UTC	DICE Therapeutics, Inc. DICE · Entity 110693	Disposition to issuerStock Option (right to buy) · Derivative	42,500	Not disclosed Strike: $19.13	Not disclosed	Disclosure SEC source: 0001209191-23-045170 · doc4.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,500 shares Expires 2032-03-31 F1 · kind: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant. Read SEC document
March 31, 2022 Filed Apr 1, 2022 18:27 UTC	DICE Therapeutics, Inc. DICE · Entity 110693	GrantStock Option (right to buy) · Derivative	42,500	$0.00 Strike: $19.13	$0.00	Disclosure SEC source: 0001209191-22-022056 · doc4.xml · derivative · entry 1 Doyle Mittie · CIK 0001918845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2032-03-31 F1 · derivative.exercise_date: The option vests as to 1/36th of the total shares on each monthly anniversary of March 31, 2022, subject to the Reporting Holder's continued service to the Registrant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.